Skip to content
TrialMatch
Sign up
Recruiting

68Ga-XACP3 PET/CT in Prostate Cancer

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The objective of the study is to construct a noninvasive approach 68Ga-XACP3 PET/CT to detect tumor lesions in patients with prostate cancer and to compare with 68Ga-PSMA PET/CT.

Condition
Prostate Cancer, PET/CT, ACP3
Tested
Diagnostic Test: standard-of-care imaging (68Ga-PSMA PET/CT), 68Ga-XACP3 PET/CT
Sponsor
The First Affiliated Hospital of Xiamen University

Who can join

Age
18 to 80 years
Sex
Male only
Healthy volunteers
Not accepted

Inclusion 8

  • Minimum age: 18 years
  • Maximum age: 80 years
  • Eligible sex: Male
  • Study condition: Prostate Cancer, PET/CT, ACP3
  • Adult patients (aged 18 years or older);
  • Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report);
  • Patients who had scheduled both standard-of-care imaging (68Ga-PSMA PET/CT) and 68Ga-XACP3 PET/CT scans;
  • Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion 1

  • The inability or unwillingness of the research participant or legal representative to provide written informed consent.

Where

1 site, 1 recruiting

The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.